California Pharmacist Vol. 73, No. 2 SPRING 2026 - Magazine - Page 34
32
Endocrinology
Loargys (pegzilarginase-nbln)
Loargys is an arginine-speci昀椀c enzyme
therapy for patients ≥2
years with hyperargininemia due to arginase
1 de昀椀ciency, lowering
arginine levels and
providing a more direct,
disease-modifying
approach than dietary
management alone.
Immedica Pharma
2/23/2026
Endocrinology
Yuviwel (navepegritide)
Yuviwel is a
once-weekly subcutaneous C-type natriuretic peptide analog
approved to increase
linear growth in pediatric patients 2 years
of age and older with
achondroplasia and
open epiphyses. Yuviwel o昀昀ers a less frequent
once-weekly dosing
regimen, representing
a potential advantage
in treatment adherence
and patient convenience.
Ascendis Pharma
2/27/2026
Gastroenterology
Lynavoy (linerixibat)
Lynavoy is the 昀椀rst ileal
bile acid transporter
inhibitor for cholestatic
pruritus in adults with
primary biliary cholangitis, reducing bile
acid–mediated itch
through a targeted
mechanism and o昀昀ering a practical, nonsystemic option compared
to traditional therapies.
GlaxoSmithKline
3/17/2026
Dermatology
Icotyde (icotrokinra)
Icotyde is approved for
the treatment of moderate-to-severe plaque
psoriasis in patients 12
years of age and older
who weigh at least 40
kg. Icotyde is the 昀椀rst
and only IL-23R targeted oral peptide pill
taken once daily.
Johnson & Johnson
3/17/2026
vol. 73, no. 2 | California Pharmacist
